Angelini Pharma just made a move. Here's exactly what to do next.
Who to reach, what to say, and why now — on Angelini Pharma, plus every M&A move, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Everyone else gives you a piece
Only Fundz delivers all four.
Acquiring Company
Angelini Pharma
Acquired Company
Catalyst Pharmaceuticals
Coral GablesBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for approximately 4.1 billion USD, equating to 31.50 USD per share in cash. This acquisition will enable Angelini Pharma to expand its footprint in the U.S. and enhance its capabilities in brain health and rare diseases. The transaction is expected to close in the third quarter of 2026, following approval from both companies' Boards of Directors.